M. Shaughnessy

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial

Christina C. Chang, J. Thakuria, N. Gerry, 2022, The Lancet.

Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial

R. Schooley, R. Dewar, J. Metcalf, 2019, The Lancet. Respiratory medicine.